Dr Srinivas Akkaraju
Srinivas Akkaraju is Founder and Managing General Partner at Samsara BioCapital. Previously he was a Managing General Partner of Sofinnova Ventures. Prior to Sofinnova, Srinivas was a Managing Director of New Leaf Venture Partners, and prior to that, a Founding Managing Director at Panorama Capital, LLC., and prior to that, a Partner with J.P. Morgan Partners.
Before his investment career, Srinivas was in Business and Corporate Development at Genentech, Inc. (now a wholly owned member of The Roche Group), a biotechnology company, most recently as Senior Manager. Dr Akkaraju currently serves as a Director of Intercept Pharmaceuticals, Inc., Seattle Genetics, Versartis Inc., and Syros Pharmaceuticals.
Previously Srinivas served as a director on the boards of ZS Pharma, Inc., Eyetech Pharmaceuticals, Inc., Synageva Biopharma Corp., aTyr Pharma, Inc., Barrier Therapeutics, Inc., and Amarin Corporation plc. Srinivas is a Board Member of The George Institute for Global.
Mr Dwayne Crombie
Mr Dawyne Crombie is Managing Director, Health Insurance Bupa Australia. Dwayne brings a wealth of experience gained across both the private and public health sectors to his role at Bupa.
Dwayne is passionate about advocating for a health system where quality improvement is part of the fabric of health care and delivering choice, value and a great joined up experience for customers and patients is equally part of our shared aspirations.
Prior to joining Bupa’s Health Insurance arm in Australia in 2013, Dwayne led Bupa’s Aged Care business in New Zealand.
Dwayne has an educational background in medicine, management and a specialist qualification in public health.
Dr Mohit Kaushal
Dr Kaushal has had an extensive career within investing, clinical medicine/academia and public policy. Mohit is an investor/board member to numerous transformational companies including Humedica (acquired by Optum Health), Rxante (acquired by Millennium), Change Healthcare (acquired by Emdeon), Universal American (NYSE:UAM) acquired by WellCare (NYSE:WCG), Gravie, Elation Health, Wellframe, CitiusTech and Oak Street Health.
During his time in the Obama administration, he was a member of the White House Health IT task force; a cross agency team implementing the technology aspects of the ACA and testified to Congress on the application of technology and payment reform Administration to the Medicare population.
He also built and led the first dedicated health care team at the Federal Communications Commission, where his team-initiated collaboration with the Food and Drug Administration for the regulatory streamlining of converged telecommunications, data analytics and medical devices leading to the release of the mobile medical applications guidance by the FDA. In addition, his team reformed the Rural Healthcare fund to create the Healthcare Connect Fund, which aligned the funding mechanism with wider health care payment policy and technology reform.
In addition, Dr Kaushal is an Adjunct Professor at Stanford University with a joint position within the newly created Biomedical Data Science Department and the medical school’s Clinical Excellence Research Center.
Dr Kaushal continues to be active within public policy and is a Scholar in Residence at the Duke Margolis Center for Health Policy. He was previously a Visiting Scholar at the Brookings Institution. He has also been appointed to the FDASIA Workgroup of the Health IT Policy Committee and to the National Committee on Vital and Health Statistics, advising HHS on Data Access and Use.
Dr Kaushal is an ER physician, holds an MBA from Stanford and an MD with distinction from Imperial College of Science, Technology and Medicine, London.
Ms Yasmin Allen
Yasmin Allen is a non-executive director of Cochlear Limited, Chairman of its Audit Committee and a member of Cochlear’s technology committee. She is also a non-executive director of ASX Limited, member of the ASX Audit Committee and ASX Clearing and Settlement board. Yasmin is a director at Santos Limited, Chairman of Santos’ Remuneration Committee and a member of its audit committee. She is also a director of the National Portrait Gallery and Chairman of Advance, connecting innovation and IP globally, and a Board Member of The George Institute for Global Health.
Yasmin’s previous directorships include Insurance Australia Group Limited (IAG) where she was Chairman of IAG’s Nomination and Remuneration Committee and a member of its Audit and Risk Committee. Yasmin was also Chairman of Macquarie Global Infrastructure Funds and a National Director of the Australian Institute of Company Directors.
Prior to her directorships, Yasmin had an extensive career in investment banking, including as Vice President of Deutsche Bank, Director of ANZ Investment Bank in Sydney and Director with HSBC in London. She has a Bachelor of Commerce from Melbourne University and in 2015 was awarded their Alumni of Distinction Award.
She is a Fellow of the Australia Institute of Company Directors and a member (and former council member) of Chief Executive Women.
Mr Neil Brown
Neil Brown is a founding member and Head of Private Equity at Federation Asset Management. Federation invests in renewable energy assets, social, health and education real estate, and growing operating companies that meet a social and economic need.
Previously, Neil was a Division Director in the balance sheet investment arm of Macquarie Bank. He has more than a decade’s experience in investment, investment management and corporate advisory across a wide range of sectors, including energy, infrastructure, transport, financials, health, and real estate.
Neil holds a Bachelor of Commerce and Economics degree with First Class Honours from the University of Queensland and is a Graduate Member of the Australian Institute of Company Directors.
Mr Staph Leavenworth Bakali
“We are a unique business with a clear mission to provide affordable, sustainable solutions that help populations have equal access to life-saving care irrespective of their location or economic situation. This is not only socially responsible, it is the foundation of a robust business opportunity. Doing good, is good business. To me it makes complete sense.”
Mustapha “Staph” Leavenworth Bakali is President and Chief Executive Officer, and Director of George Health. Previously Mr Leavenworth Bakali was President and Chief Operating Officer of the Clinton Health Access Initiative (CHAI). Mr Leavenworth Bakali has 30 years of considerable senior executive and board level experience in leading, growing, and transforming large complex and start up organisations in both developed and emerging markets in the global pharmaceutical, biotechnology and not-for profit health arenas.
Prior to CHAI, he held several senior executive and Board positions with leading pharmaceutical and biotechnology companies, including 11 years with SmithKline Beecham living and managing businesses in French West Africa, Latin America, and Europe.
Mr Leavenworth Bakali has substantial experience and a proven track record in fundraising, negotiating and concluding a wide range of public and private sector agreements and partnerships, including cross border mergers and acquisitions. As Chief Operation Officer of Vancouver-based ID Biomedical and UK-based PowderJect Pharmaceuticals Plc, he played a significant role in transforming the two companies from R&D organizations into fully-integrated biotech companies leading to subsequent acquisitions by GlaxoSmithKline and Chiron Corporation, respectively. As Worldwide Head of Sales and Marketing of Chiron Corporation’s Vaccines Division, he played an instrumental role in negotiating the partnerships that led to the eventual development of a low-cost combination pentavalent vaccine to serve children across the world’s 70 poorest countries. Mr Leavenworth Bakali is also the co-founder of LeapFrog Investments, the world’s first and largest investor in companies that insure underserved people in Africa and Asia.
Mr Leavenworth Bakali serves on a number of boards as an advisor and as a non-Executive Director and Chairman. He holds a First Class Honours Degree from City of London Polytechnic and an MSc (With Distinction) from London Business School.
Mr Scott Featherston
Scott is Chief Financial Officer and Director for Corporate Development for George Health and is an Honorary Professorial Fellow at The George Institute. Scott also has interests in education. He founded Caerus Capital, a boutique private investment firm that invests in the private education sector in Sub-Saharan Africa and he sits on the board of Luminus Education in Amman, Jordan.
Scott was formerly the Global Health Sector Leader and a Principal Investment Officer for the International Finance Corporation (IFC), the private sector arm of the World Bank Group. During his time at IFC (2005-2015), Scott led numerous transactions in the health and education sectors in Africa, MENA, South/East Asia, and Europe and founded the World Bank’s Health in Africa initiative. Scott’s early career was in engineering and finance.
He worked for a global property and project management firm before joining the finance advisory practice of a “Big 4” global consulting firm. Scott holds masters degrees in international affairs and engineering science.
He lectured in international economics and finance at the Johns Hopkins School of Advanced International Studies in Washington DC.
Mr Glenn Kerkhof
Glenn Kerkhof is Executive Chairman of George Clinical. Glenn has over 27 years’ experience in the contract research or drug development industry and joined George Clinical from Chiltern, where he was Chief Executive Officer.
Before Chiltern, Glenn served as Vice President, Clinical Services for Charles River Laboratories, and as Vice President, Clinical Europe for Inveresk Research. Also, he is a non-executive director of Immunoglobal Pty. Ltd and his previous directorships include Cell Care Pty. Ltd. Glenn, based in Melbourne, works closely with the executive team to formulate and execute George Clinical’s global strategy.
Professor John Knight
An experienced children’s kidney specialist, John is Managing Director of Ellen Medical Devices. John also works as a Professorial Fellow with The George Institute for Global Health. He is a Professor of Medicine at UNSW Sydney and an Adjunct Professor of Paediatrics and Child Health at The Children’s Hospital, Westmead. John was previously a Vice President at Johnson and Johnson.
Since joining The George Institute in March 2014, John has contributed to a variety of academic and business projects in Australia, in China and with George Clinical. His current research at The George Institute includes a prospective national cohort study of Dialysis Outcomes in India, and an epidemiological study of chronic kidney disease of unknown origin in Sri Lanka.
In 2015 John convened the Steering Committee and chaired the Judges Panel for the Affordable Dialysis Prize. Ellen Medical Devices Pty Ltd is an Australian company founded to build and test a prototype of the winning entry.
Mr Stefan König
Stefan was appointed CEO of George Medicines in June 2021, joining from Takeda Pharmaceuticals where his most recent role was Vice-President and Global Franchise Head Inflammatory Bowel Disease (IBD). In his role, he was responsible for Takeda ́s most significant asset Entyvio (vedolizumab). Under Stefan ́s leadership the vedolizumab franchise grew to become the gold standard therapy for IBD patients with around USD 4bn in global revenues and a significant lifecycle plan for further, sustained expansion. In this role Stefan chaired the senior, cross-functional Global Program Team (GPT) and oversaw design of global commercial strategy, guiding execution to regions and affiliates. During his tenure Stefan shaped not only Takeda ́s first global biologic franchise, but also oversaw multiple, innovative partnerships across IBD and devices.
Prior to that, Stefan was the General Manager for Takeda in Austria, where he led integration of the significant Takeda and Nycomed legacy organisations and transformed the business from a Primary Care organisation to become an agile specialty care and oncology player. Given his passion for market access, Stefan also held the position as Vice-Chair of the Board of the National Industry Association in Austria and had an active role to shaping the local healthcare environment.
Stefan ́s earlier roles at Takeda included Regional Managing Director for a cluster of countries in Central and Eastern Europe, based in Slovenia. Stefan also spent almost 10 years in Mexico and Latin America, working in areas such as business and corporate development and marketing for various companies, including Novartis and Merck KGaA/EMDSerono.
Dr Karl Roberts
Dr Roberts has over 30 years’ experience in various commercial, general management, consultant and strategic roles in both the branded and generic pharma space and in contract manufacturing.
Karl has extensive global experience in strategic licensing and M&A and a proven track record in brokering deals in both established and emerging markets.
Prior to joining the George Health team Dr Roberts was Global Head of Business Development at Concordia and prior to that led Cipla’s business in Western Europe for over 5 years where he was instrumental in reshaping and delivering their European growth strategy.
Dr Nina Desai
Dr Nina brings extensive experience in digital health strategy and health system technology solutions in Asia, the Middle East, Europe and the US. She has worked across public and private healthcare providers and payers, industry and academia and brings deep expertise in health system funding and integrated healthcare delivery models.
Prior to her role at George Health, she built a diverse portfolio of population health products and services in her role at Optum International. While Director of Global Health at Swiss Re, she led the development of the organisation’s health and care strategy in Asia, Europe and the US. She has also worked extensively with digital health start-ups as well as providers and government policy makers to develop, test and scale innovative digital health models.
Dr Nina is an internal medicine physician with a public health degree from Mount Sinai Medical School and a bachelor’s degree in applied mathematics from Brown University.
Professor Robyn Norton AO
Robyn is Co-Founder of The George Institute for Global Health and Acting Executive Director, The George lnstitute for Global Health, University of Oxford. She is a Board Member of The George Institute for Global Health and of George Health and a Professor of Public Health, Faculty of Medicine, UNSW Sydney; Professor of Global Health and Oxford Martin Senior Fellow, University of Oxford; and Honorary Professor, Peking University.
Robyn has published widely and is internationally regarded for her research on the causes, prevention and management of injuries, especially road traffic and fall-related injuries, as well as the management of various critical conditions in surgical and intensive care settings.
Robyn has had a long-standing commitment to improving women’s health and currently leads The George Institute’s research, implementation and advocacy program, which aims to improve the health of women and girls worldwide.
Professor Stephen MacMahon AO
“We founded The George Institute 20 years ago to find ways to help developing countries stem the rising tide of chronic diseases facing both young and old. Since then we have developed a range of drugs, technologies and system solutions that are highly effective in resource-poor setting. We established George Health to commercialise these and ensure their scale-up. We want to harness the power of the private sector to provide financially sustainable health care to the huge numbers facing early death or disability from chronic but treatable conditions.”
Co-founder of The George Institute and George Health, Stephen is a leading authority on the treatment of non-communicable diseases as well as a recognised social entrepreneur.
Stephen is a Professor of Medicine and Oxford Martin Senior Fellow, University of Oxford; Professor of Cardiovascular Medicine, UNSW Sydney; Honorary Professor, Peking University Health Science Center; Honorary Consultant, Royal Prince Alfred Hospital (Sydney); and a Fellow of the Australian Academy of Sciences, Australian Academy of Health and Medical Sciences, British Academy of Medical Sciences and American College of Cardiology.
Stephen was named EY Social Entrepreneur of the Year in 2013.